News - ThromboGenics, Research

Filter

Current filters:

ThromboGenicsResearch

Popular Filters

Ph III trials show Novartis' Jetrea improves vitreomacular traction

17-08-2012

Swiss drug major Novartis (NOVN: VX) that the New England Journal of Medicine (NEJM) this week published…

AlconJetreaNovartisocriplasminOphthalmicsPharmaceuticalResearchThromboGenics

ThromboGenics confident as it plans for ocriplasmin launch

12-03-2012

Belgian biopharma firm ThromboGenics (Euronext Brussels: THR) says that, over the past 12 months, it…

BiotechnologyFinancialocriplasminOphthalmicsRegulationResearchThromboGenics

Positive new Ph III data on ThromboGenics’ ocriplasmin

22-08-2011

Belgian ophthalmic drug developer ThromboGenics (Euronext Brussels: THR) has presented strong new data,…

ocriplasminOphthalmicsPharmaceuticalResearchThromboGenics

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top